Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiraterone acetate plus prednisone in Asian patients with mCRPC post-docetaxel
NCT01695135Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2012
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Abiraterone acetate plus prednisone with Placebo plus prednisone (2 arms). Primary endpoint: Time to Prostate-Specific Antigen Progression up to 1.8 years. Started Aug 2012; status: completed.
02
Drugs
Abiraterone Acetate Tablets (I)
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01695135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01695135.